Anixa Biosciences
ANIX
32 hedge funds and large institutions have $11.5M invested in Anixa Biosciences in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
100% more call options, than puts
Call options by funds: $118K | Put options by funds: $59K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 29 → 32 (+3)
1.86% more ownership
Funds ownership: 8% → 9.86% (+1.9%)
3% less capital invested
Capital invested by funds: $11.8M → $11.5M (-$303K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$530K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$425K |
| 3 |
Two Sigma Investments
New York
|
+$223K |
| 4 |
Two Sigma Advisers
New York
|
+$204K |
| 5 |
Morgan Stanley
New York
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$122K |
| 2 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$94K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$83.8K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$62K |
| 5 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
-$37.9K |
ANIX Hedge Fund Activity: Q2 2021 in Review
32 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2021, worth a combined $11.5M — down 2.6% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ANIX positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $530K. The largest seller was Jane Street, exiting entirely with an estimated $122K sold.
- 32 institutional investors held Anixa Biosciences (ANIX) as of Q2 2021, up from 29 in Q1 2021.
- Funds reported $11.5M of Anixa Biosciences stock for Q2 2021, down 2.6% quarter-over-quarter.
- 8 funds opened new Anixa Biosciences positions in Q2 2021 and 5 closed out, a net change of +3 holders.
- The largest Anixa Biosciences buyer in Q2 2021 was Renaissance Technologies, an estimated $530K added.
- The largest Anixa Biosciences seller in Q2 2021 was Jane Street, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2021.